Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New glasses could slow Kids' worsening eyesight

NCT ID NCT06263946

Disease control Sponsor: Essilor International Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 21, 2026 · Updated 2 times

Summary

This study tests whether Essilor Stellest spectacle lenses can slow the progression of myopia (nearsightedness) in children and teens aged 6 to 16. One hundred fifty participants will wear the lenses for at least 12 hours a day over 24 months. Researchers will measure changes in eye length and prescription strength to see if the lenses work better than expected natural progression.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Essilor Stellest spectacle lenses
What this could lead to
If successful, these lenses could offer a simple, non-invasive way to slow worsening nearsightedness in children, reducing the need for stronger prescriptions.
What could go wrong
This is a post-market study with no control group, so results may be less definitive. The lenses require full-time wear for 2 years, and not all children may see the same benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2024

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 16 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. \- Myopia as determined by cycloplegic autorefraction as follows: * Each meridian SER of plano to - 8;00 D in each eye * Astigmatism \< 2.50 D * Anisometropia ≤ 1.50 D 2. \- Monocular corrected VA of at least 0.2 LogMAR in both eyes 3. \- Age: 6 - 16 years old, inclusive at the time of inclusion 4. \- Ability to understand treatment and give valid assent 5. \- Ability to comply with the protocol to get reliable study measurements Exclusion Criteria: 1. \- Concomitant or previous therapies for myopia 2. \- Eye diseases/conditions: * Strabismus by cover test at near or distance * Any ocular disease that would influence refractive development e.g. retinal disease, cataract, ptosis * Any systemic or neurodevelopmental conditions that may influence refractive development 3. \- Use of ocular or systemic medication which may affect myopia progression or visual acuity through known effects on retina, accommodation, or significant elevation of intraocular pressure 4. \- Participation in another study which may influence vision or interfere with study assessments 5. \- Myopia onset before 5 years of age 6. \- Contact lens wearers

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myopia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myopia

Contacts and locations

Locations

  • Centre for Eye Research Ireland (CERI) - TU DUBLIN

    Dublin, D07 H6K8, Ireland

  • Erasmus Medical Center

    Rotterdam, 3015, Netherlands

  • Hôpital Fondation Adolphe de Rothschild - Ophthalmology Department

    Paris, 75019, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.